GLP-1 ↔ GLP-1+GIP genetic interpretation for obesity therapy

International scientific and medical community

Genetic test interpretation calculator for selecting a priority drug for obesity treatment

A tool supporting physician interpretation of four single-nucleotide variants (SNPs) associated with expected sensitivity to GLP-1 therapy, the risk of gastrointestinal (GI) reactions, and auxiliary DPP4 assessment.

Data entry form

SNP1
GLP1R · rs10305420 · c.20C>T

The interpreted allele is T, the primary marker of GLP-1 sensitivity.

SNP2
GIPR · rs1800437 · c.1060G>C

The interpreted allele is C, a marker of the risk of GI reactions during GLP-1+GIP therapy.

SNP3
GLP1R · rs6923761 · c.502G>A

The interpreted allele is A, an additional modifier of GLP-1 sensitivity.

SNP4
DPP4 · rs6741949 · NC_000002.12:g.162053713G>C

The interpreted allele is C, an auxiliary DPP4 modifier.

T2D
Type 2 diabetes

Select this if the patient has a confirmed diagnosis of type 2 diabetes.

Reset

Additional background

Why genetic context is needed when selecting incretin therapy

Obesity is regarded as a complex biological condition in which the response to treatment is influenced by appetite, incretin regulation, glucose metabolism, treatment tolerability, and individual receptor characteristics.

The calculator for interpreting a genetic test panel for selecting a drug for obesity treatment is not a broad "obesity test". It focuses on four variants in GLP1R, GIPR, and DPP4 that help the physician clarify the expected sensitivity to GLP-1 therapy, the risk of gastrointestinal reactions during GLP-1+GIP therapy, and a possible titration strategy.

Tasks performed by the genetic calculator:

  1. Matching the GLP1R profile with the probability of a clinically meaningful response to GLP-1 therapy;
  2. Assessing the need for a more cautious start to combined GLP-1+GIP therapy;
  3. Considering DPP4 as an auxiliary marker of endogenous incretin regulation;
  4. Developing a realistic treatment strategy before initiating or reassessing therapy.

The result reduces uncertainty, but does not select a drug in place of the physician. The final regimen depends on BMI (body mass index), type 2 diabetes, contraindications, laboratory values, drug availability, tolerability, and treatment goals.

Scientific rationale and reference materials

The interpretation is based on scientific papers on the pharmacogenetics of GLP-1+GIP therapy, clinical trials of the drugs, and official prescribing information.

Primary sources

  • Nature 2026Key pharmacogenetic paper on GLP1R rs10305420 and GIPR rs1800437: expected response to GLP-1 therapy and risk of GI reactions.
  • PLOS One 2017Primary source for DPP4 rs6741949 as an auxiliary marker of incretin regulation in the setting of high fat mass.
Show additional sources
  • NEJM STEP 1 2021Foundational clinical trial of semaglutide 2.4 mg in adults with obesity or overweight without T2D.
  • NEJM SURMOUNT-1 2022Foundational clinical trial of tirzepatide in adults with obesity or overweight without T2D.
  • FDA Wegovy labelOfficial prescribing information for semaglutide: indications, starting dose, titration, warnings, and safety profile.
  • FDA Zepbound labelOfficial prescribing information for tirzepatide: dual GIP/GLP-1 mechanism, doses, titration, and GI tolerability.
  • Global GLP-1/GIP medicine registerGlobal register of GLP-1/GIP medicines: active ingredients, brand names, manufacturers, and countries of registration.

This tool does not replace clinical assessment, current prescribing information for the drugs, or local protocols.